JPMorgan Resumes Nektar Therapeutics (NKTR) at Neutral
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $74.54 +0.01%
Rating Summary:
20 Buy, 8 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
20 Buy, 8 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
JPMorgan analyst Jessica Fye resumes coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Neutral rating and a price target of $26.00.
For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.
Shares of Nektar Therapeutics closed at $18.82 yesterday.
You May Also Be Interested In
- JPMorgan Reinstates Nektar Therapeutics (NKTR) at Neutral
- BofA Securities Starts Mobility Global (MBGL) at Neutral
- D. Boral Capital Starts Eve Holding Inc. (EVEX) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
